Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 4:09 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 540788 | NSE: ASPIRA

Aspira Pathlab & Diagnostics Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹158.53Undervalued by 169.15%vs CMP ₹58.90

P/E (41.3) × ROE (33.6%) × BV (₹14.00) × DY (2.00%)

₹51.43Overvalued by 12.68%vs CMP ₹58.90
MoS: -14.5% (Negative)Confidence: 56/100 (Moderate)Models: 1 Under, 6 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹127.0229%Under (+115.7%)
Graham NumberEarnings₹21.2217%Over (-64%)
DCFCash Flow₹11.0517%Over (-81.2%)
Net Asset ValueAssets₹14.029%Over (-76.2%)
EV/EBITDAEnterprise₹46.0411%Over (-21.8%)
Earnings YieldEarnings₹14.309%Over (-75.7%)
Revenue MultipleRevenue₹21.387%Over (-63.7%)
Consensus (7 models)₹51.43100%Overvalued
Key Drivers: EPS CAGR -19.9% drags value — could be higher if earnings stabilize. | Wide model spread (₹11–₹127) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -19.9%

*Investments are subject to market risks

Investment Snapshot

67
Aspira Pathlab & Diagnostics Ltd scores 67/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health75/100 · Strong
ROCE 17.4% GoodROE 33.6% ExcellentD/E 0.00 Low debtInterest Coverage 0.0x RiskyProfitable 3/5 years Mixed
Smart Money50/100 · Moderate
Promoter holding at 18.4% Stable
Earnings Quality50/100 · Moderate
OPM contracting (22% → 4%) DecliningWorking capital: 14 days (improving) Efficient
Quarterly Momentum80/100 · Strong
Revenue (4Q): +21% YoY AcceleratingProfit (4Q): +73% YoY StrongOPM: -23.6% (down 37.7% YoY) Margin pressure
Industry Rank70/100 · Strong
P/E 41.3 vs industry 75.2 Cheaper than peersROCE 17.4% vs industry 14.7% AverageROE 33.6% vs industry 13.9% Above peers3Y sales CAGR: 4% Slow

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 4:09 am

Market Cap 60.6 Cr.
Current Price 58.9
Intrinsic Value₹51.43
High / Low 81.0/50.5
Stock P/E41.3
Book Value 14.0
Dividend Yield0.00 %
ROCE17.4 %
ROE33.6 %
Face Value 10.0
PEG Ratio-2.08

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Aspira Pathlab & Diagnostics Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Aspira Pathlab & Diagnostics Ltd 60.6 Cr. 58.9 81.0/50.541.3 14.00.00 %17.4 %33.6 % 10.0
Dr Lal Pathlabs Ltd 22,178 Cr. 1,324 1,771/1,17640.4 1430.91 %28.9 %24.3 % 10.0
Thyrocare Technologies Ltd 5,762 Cr. 362 538/22043.8 32.41.93 %26.5 %17.4 % 10.0
Sakar Healthcare Ltd 1,147 Cr. 516 578/22045.5 1360.00 %8.54 %6.48 % 10.0
Artemis Medicare Services Ltd 3,528 Cr. 223 306/20335.5 56.00.20 %14.9 %12.9 % 1.00
Industry Average26,819.31 Cr611.5975.1783.710.36%14.71%13.91%9.04

All Competitor Stocks of Aspira Pathlab & Diagnostics Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 4.373.412.603.323.463.824.646.185.415.785.258.095.12
Expenses 3.563.262.923.683.833.954.294.834.654.734.445.906.33
Operating Profit 0.810.15-0.32-0.36-0.37-0.130.351.350.761.050.812.19-1.21
OPM % 18.54%4.40%-12.31%-10.84%-10.69%-3.40%7.54%21.84%14.05%18.17%15.43%27.07%-23.63%
Other Income 0.120.070.100.140.100.080.090.080.090.130.110.140.13
Interest 0.100.100.100.100.090.080.080.080.090.090.090.100.10
Depreciation 0.390.380.390.390.380.380.380.360.390.370.370.400.38
Profit before tax 0.44-0.26-0.71-0.71-0.74-0.51-0.020.990.370.720.461.83-1.56
Tax % 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Net Profit 0.44-0.26-0.72-0.71-0.74-0.50-0.020.990.380.720.471.84-1.56
EPS in Rs 0.43-0.25-0.70-0.69-0.72-0.49-0.020.960.370.700.461.79-1.52

Last Updated: March 3, 2026, 12:08 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 11:05 pm

MetricMar 2012Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 0.000.000.000.764.367.648.4215.2119.5414.4613.2022.0024.24
Expenses 0.020.140.233.348.2410.8810.2511.6913.1612.8614.3818.4421.40
Operating Profit -0.02-0.14-0.23-2.58-3.88-3.24-1.833.526.381.60-1.183.562.84
OPM % -339.47%-88.99%-42.41%-21.73%23.14%32.65%11.07%-8.94%16.18%11.72%
Other Income 0.020.210.320.310.220.250.290.200.090.320.420.360.51
Interest 0.000.000.050.260.800.961.010.890.370.420.370.350.38
Depreciation 0.000.000.000.201.121.231.661.441.641.591.541.491.52
Profit before tax 0.000.070.04-2.73-5.58-5.18-4.211.394.46-0.09-2.672.081.45
Tax % 57.14%25.00%0.00%0.00%0.00%0.71%0.00%0.00%0.00%0.00%0.00%
Net Profit 0.000.020.03-2.72-5.58-5.18-4.241.384.46-0.09-2.672.071.47
EPS in Rs 0.000.090.13-5.24-10.75-6.32-4.561.344.33-0.09-2.592.011.43
Dividend Payout % 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)50.00%-9166.67%-105.15%7.17%18.15%132.55%223.19%-102.02%-2866.67%177.53%
Change in YoY Net Profit Growth (%)0.00%-9216.67%9061.52%112.32%10.98%114.40%90.64%-325.21%-2764.65%3044.19%

Aspira Pathlab & Diagnostics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:%
5 Years:21%
3 Years:4%
TTM:48%
Compounded Profit Growth
10 Years:59%
5 Years:20%
3 Years:-23%
TTM:230%
Stock Price CAGR
10 Years:%
5 Years:26%
3 Years:13%
1 Year:99%
Return on Equity
10 Years:%
5 Years:17%
3 Years:-3%
Last Year:24%

Last Updated: September 5, 2025, 2:26 pm

Balance Sheet

Last Updated: February 1, 2026, 2:23 am

MonthMar 2012Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 0.402.252.255.195.198.199.2910.2910.2910.2910.2910.2910.29
Reserves 0.191.361.390.72-4.86-7.93-10.42-6.91-2.43-2.47-5.08-3.014.13
Borrowings 0.000.002.627.2911.3612.5213.807.018.858.247.718.133.13
Other Liabilities 0.030.210.031.660.842.021.671.391.421.281.792.112.61
Total Liabilities 0.623.826.2914.8612.5314.8014.3411.7818.1317.3414.7117.5220.16
Fixed Assets 0.000.000.047.797.918.908.707.759.578.016.796.536.71
CWIP 0.000.000.000.250.000.000.000.000.000.000.000.000.00
Investments 0.000.000.000.000.000.000.000.000.000.000.000.130.00
Other Assets 0.623.826.256.824.625.905.644.038.569.337.9210.8613.45
Total Assets 0.623.826.2914.8612.5314.8014.3411.7818.1317.3414.7117.5220.16

Reserves and Borrowings Chart

Cash Flow

MonthMar 2012Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + -0.02-0.37-1.29-4.81-3.39-1.875.672.03-0.011.051.88
Cash from Investing Activity + 0.08-0.02-10.14-0.77-1.970.24-0.09-0.510.160.140.07
Cash from Financing Activity + -0.062.648.916.523.351.27-2.17-1.35-0.94-0.95-0.99
Net Cash Flow 0.002.25-2.520.94-2.00-0.353.410.17-0.790.240.95
Free Cash Flow -0.02-0.41-8.41-5.81-3.90-1.925.371.42-0.150.791.71
CFO/OP 50%139%50%124%105%101%161%32%-1%-89%53%

Free Cash Flow

MonthMar 2012Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-0.02-0.14-2.85-9.87-15.24-15.76-15.63-3.49-2.47-6.64-8.89-4.57

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2012Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 43.2229.3038.2226.0140.8083.8759.0761.9438.99
Inventory Days 312.86103.8845.2251.3651.3546.5058.4062.6950.31
Days Payable 730.0064.5846.8473.3791.6070.9151.10101.7073.00
Cash Conversion Cycle -373.9268.6136.604.000.5559.4666.3722.9316.30
Working Capital Days -2,199.61-5.86-96.03-127.0116.3269.3048.7225.1614.10
ROCE %0.00%1.82%-25.39%-38.41%-34.49%-25.15%19.77%35.65%2.01%-15.87%17.37%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 19.47%19.37%18.90%18.90%18.72%18.72%18.55%18.55%18.39%18.39%18.39%18.39%
Public 80.53%80.64%81.10%81.10%81.29%81.28%81.46%81.46%81.62%81.62%81.61%81.61%
No. of Shareholders 1,3001,3711,4061,3511,5121,6951,7061,5931,7411,7701,7551,784

Shareholding Pattern Chart

No. of Shareholders

Aspira Pathlab & Diagnostics Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24
FaceValue 10.0010.00
Basic EPS (Rs.) 1.97-2.60
Diluted EPS (Rs.) 1.97-2.60
Cash EPS (Rs.) 3.46-1.10
Book Value[Excl.RevalReserv]/Share (Rs.) 7.035.07
Book Value[Incl.RevalReserv]/Share (Rs.) 7.035.07
Revenue From Operations / Share (Rs.) 21.3712.83
PBDIT / Share (Rs.) 3.80-0.74
PBIT / Share (Rs.) 2.35-2.24
PBT / Share (Rs.) 2.01-2.60
Net Profit / Share (Rs.) 2.01-2.60
NP After MI And SOA / Share (Rs.) 1.97-2.60
PBDIT Margin (%) 17.79-5.79
PBIT Margin (%) 11.00-17.45
PBT Margin (%) 9.42-20.23
Net Profit Margin (%) 9.42-20.23
NP After MI And SOA Margin (%) 9.19-20.23
Return on Networth / Equity (%) 27.94-51.25
Return on Capital Employeed (%) 16.03-18.23
Return On Assets (%) 11.58-18.16
Asset Turnover Ratio (%) 1.370.00
Current Ratio (X) 2.262.10
Quick Ratio (X) 2.051.89
Inventory Turnover Ratio (X) 45.900.00
Interest Coverage Ratio (X) 11.27-2.08
Interest Coverage Ratio (Post Tax) (X) 6.97-6.27
Enterprise Value (Cr.) 86.7931.60
EV / Net Operating Revenue (X) 3.952.39
EV / EBITDA (X) 22.18-41.27
MarketCap / Net Operating Revenue (X) 3.992.42
Price / BV (X) 12.126.12
Price / Net Operating Revenue (X) 3.992.42
EarningsYield 0.02-0.08

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Aspira Pathlab & Diagnostics Ltd. is a Public Limited Listed company incorporated on 03/07/1973 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L85100MH1973PLC289209 and registration number is 289209. Currently Company is involved in the business activities of Other human health activities. Company's Total Operating Revenue is Rs. 22.00 Cr. and Equity Capital is Rs. 10.29 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Hospitals & Medical ServicesFlat No.2, R.D. Shah Building, Mumbai Maharashtra 400086Contact not found
Management
NamePosition Held
Dr. Haseeb A DrabuChairman & Ind.Director
Dr. Pankaj J ShahManaging Director & CEO
Mr. Nikunj V MangeExecutive Director
Mrs. Mangala R PrabhuIndependent Director
Dr. Manas R MengarIndependent Director

FAQ

What is the intrinsic value of Aspira Pathlab & Diagnostics Ltd and is it undervalued?

As of 14 April 2026, Aspira Pathlab & Diagnostics Ltd's intrinsic value is ₹51.43, which is 12.68% lower than the current market price of ₹58.90, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (33.6 %), book value (₹14.0), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Aspira Pathlab & Diagnostics Ltd?

Aspira Pathlab & Diagnostics Ltd is trading at ₹58.90 as of 14 April 2026, with a FY2026-2027 high of ₹81.0 and low of ₹50.5. The stock is currently in the middle of its 52-week range. Market cap stands at ₹60.6 Cr..

How does Aspira Pathlab & Diagnostics Ltd's P/E ratio compare to its industry?

Aspira Pathlab & Diagnostics Ltd has a P/E ratio of 41.3, which is below the industry average of 75.17. This is broadly in line with or below the industry average.

Is Aspira Pathlab & Diagnostics Ltd financially healthy?

Key indicators for Aspira Pathlab & Diagnostics Ltd: ROCE of 17.4 % indicates efficient capital utilization; ROE of 33.6 % shows strong shareholder returns. Dividend yield is 0.00 %.

Is Aspira Pathlab & Diagnostics Ltd profitable and how is the profit trend?

Aspira Pathlab & Diagnostics Ltd reported a net profit of ₹2 Cr in Mar 2025 on revenue of ₹22 Cr. Compared to ₹4 Cr in Mar 2022, the net profit shows a declining trend.

Does Aspira Pathlab & Diagnostics Ltd pay dividends?

Aspira Pathlab & Diagnostics Ltd has a dividend yield of 0.00 % at the current price of ₹58.90. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Aspira Pathlab & Diagnostics Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports